Cover Image
市場調查報告書

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 288828
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析 Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 46 Pages
簡介

由於抗藥性金黃色葡萄球菌(MRSA)具有對包含甲氧西林在內的部分抗生素之抗藥性,所以具有難以殺菌的特徵。此外,MRSA往往跟醫院、醫療機關治療行為有關。主要的致病因素有住院、使用侵襲性醫療設備、及長期住院等。遵守衛生手續是降低感染該細菌風險之方法。

本報告提供全球各國治療院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:企業開發中的治療藥

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:大學/機關研究中的治療藥

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:企業開發中的產品

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:大學/機關研究中的產品

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析的治療藥開發企業

  • Destiny Pharma Limited
  • Galapagos NV
  • MGB Biopharma Limited
  • Syntiron LLC
  • Techulon, Inc.

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:最近的開發平台趨勢

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:暫停中的計劃

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:中止開發的產品

院內感染型MRSA (抗藥性金黃色葡萄球菌) 感染疾病:開發中產品分析:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8208IDB

Summary

Global Markets Direct's, 'Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016', provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • The report reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics and enlists all their major and minor projects
  • The report assesses Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview
    • Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Development by Companies
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Investigation by Universities/Institutes
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Development by Companies
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Investigation by Universities/Institutes
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development
    • Destiny Pharma Limited
    • Galapagos NV
    • MGB Biopharma Limited
    • Syntiron LLC
    • Techulon, Inc.
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acALY-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • exeporfinium chloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1492 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MH-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Staphylococcus aureus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Recent Pipeline Updates
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2016
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Limited, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Galapagos NV, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Limited, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H1 2016
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H1 2016
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top